381 related articles for article (PubMed ID: 22050339)
1. Targeting T cells with bispecific antibodies for cancer therapy.
Lum LG; Thakur A
BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
[TBL] [Abstract][Full Text] [Related]
2. The new face of bispecific antibodies: targeting cancer and much more.
Lum LG; Davol PA; Lee RJ
Exp Hematol; 2006 Jan; 34(1):1-6. PubMed ID: 16413384
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
5. Retargeting T cells and immune effector cells with bispecific antibodies.
Lum LG; Davol PA
Cancer Chemother Biol Response Modif; 2005; 22():273-91. PubMed ID: 16110617
[TBL] [Abstract][Full Text] [Related]
6. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
8. Redirecting cytotoxic T cells with chemically programmed antibodies.
Qi J; Rader C
Bioorg Med Chem; 2020 Dec; 28(24):115834. PubMed ID: 33166926
[TBL] [Abstract][Full Text] [Related]
9. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
10. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
Yu L; Wang J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
[TBL] [Abstract][Full Text] [Related]
11. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
12. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
13. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
Lum LG; Sen M
Acta Haematol; 2001; 105(3):130-6. PubMed ID: 11463985
[TBL] [Abstract][Full Text] [Related]
14. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True.
D'Agostino M; Innorcia S; Boccadoro M; Bringhen S
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33139668
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done.
Tang J; Shen D; Zhang J; Ligler FS; Cheng K
Expert Opin Biol Ther; 2015; 15(9):1251-5. PubMed ID: 26004388
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
18. Chemically programmed bispecific antibodies that recruit and activate T cells.
Cui H; Thomas JD; Burke TR; Rader C
J Biol Chem; 2012 Aug; 287(34):28206-14. PubMed ID: 22761439
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies for cancer therapy.
Chames P; Baty D
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]